# OnCo record paper-future-super-lancet-oncology-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-future-super-lancet-oncology-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-future-super-lancet-oncology-2024" ;
  schema:name "FUTURE-SUPER: first-line subtyping-based treatment in advanced TNBC"@en ;
  schema:description "This randomised phase 2 trial found longer progression-free survival with a specified subtype-based combination strategy than with nab-paclitaxel alone, with more serious treatment-related adverse events."@en ;
  schema:url <https://onco.cc/key-papers/paper-future-super-lancet-oncology-2024/> ;
  schema:dateModified "2026-11-09"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/38211606/>, <https://clinicaltrials.gov/study/NCT04395989> ;
  onco:tag "education-audit", "randomised-phase-2" ;
  schema:sameAs <https://doi.org/10.1016/s1470-2045(23)00579-x> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Fan L, Wang ZH, Ma LX, Wu SY, Wu J, Yu KD, Sui XY, Xu Y, Liu XY, Chen L, Zhang WJ, Jin X, Xiao Q, Shui RH, Xiao Y, Wang H, Yang YS, Huang XY, Cao AY, Li JJ, Di GH, Liu GY, Yang WT, Hu X, Xia Y, Liang QN, Jiang YZ, Shao ZM." ;
  onco:related <https://onco.cc/terms/tnbc-molecular-subtyping/>, <https://onco.cc/terms/pam50/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/> ;
  onco:trials <https://onco.cc/trials/future-super/> .
